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PHYSICIAN BELIEFS ABOUT INSULIN PENS VERSUS VIALS, THERAPY CHOICE
FACTORS, AND PATIENT CHARACTERISTICS AMONG ELDERLY TYPE 2
DIABETES PATIENTS
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OBJECTIVES: To assess physician beliefs on the relative benefits of pens vs. vials,
prescribing drivers, and characteristics of patients newly initiated on basal insulin
analog via pens vs. vials among elderly type 2 diabetes patients. METHODS: An
online survey of 352 U.S. primary care physicians was used to collect retrospective
patient chart data on 500 elderly type 2 diabetes patients who initiated on basal
insulin analog in 2009. For each physician, patient chart selection was randomized
among eligible patients. Data on physician characteristics, physicians’ opinion on
the impact of different routes of administration (ROA), main drivers for selecting a
particular ROA for each patient, and patient characteristics were collected.
RESULTS: The majority of physician respondents were part of a group practice
(77.8%) and treated a mean of 235.5 (SD185.0) type 2 patients  65 years old in
2009. Patient characteristics were similar in terms of age and diabetes duration.
However, significantly more Caucasians (p  0.011) and patients covered by Medi-
care only (p0.015) were initiated on pens, whereas significantly more women
(p0.003), Black/African Americans (p0.011), and dual eligible patients (Medicare
Medicaid; p0.008) were initiated on vials. Patients initiated on vials had higher
median baseline HbA1c values (8.7 vs. 8.4, p0.001).Survey findings suggested that
physicians prescribed vials primarily due to patients’ economic constraints (62.9%
of vial users vs. only 2.4% for pen users), although a majority of physicians consid-
ered pens better than vials (89.2% in terms of adherence, 65.1% in terms of HbA1c
control, and 55.4% in terms of resource utilization). CONCLUSIONS: Results from
this retrospective chart extraction survey suggest that patient characteristics dif-
fered between patients initiated on pens vs. vials, and that despite insulin pens
being perceived as having better outcomes by physicians, economic considerations
play a dominant role in the choice of insulin vials.
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THE USE OF LIRAGLUTIDE IN PRIMARY CARE
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OBJECTIVES: Liraglutide, a GLP-1 receptor agonist used to treat Type 2 diabetes
patients, is reimbursed in Ireland since November 2009. Budget impact analysis at
this time assumed use of the 1.2mg dose in 95% of patients. A 1.8mg maintenance
dose is also available. The aim of this study was to examine utilisation of liraglutide
in the post reimbursement ‘real world’ setting. METHODS: Data were analysed
using a national prescription claims database from November 2009 to December
2011. Numbers of patients receiving prescriptions for liraglutide and exenatide
were calculated per month and the average number of pens dispensed per pre-
scription and duration of use was analysed for liraglutide. Drugs were classified
and identified according to the WHO ATC classification system. Analysis was per-
formed in SAS (v9.1). RESULTS: The number of prescriptions for liraglutide in-
creased from 0.3 to 0.9/1000 GMS population over the study period. The number of
exenatide prescriptions decreased from 0.3 to 0.15/1000 GMS population. Fifty per-
cent of patients dispensed liraglutide in 2010 and 2011 received 1.8mg per prescrip-
tion. The average duration of use of liraglutide ranged from  3 months (41% of
patients),  6 months (26% of patients),  9 months (18% of patients) and  12
months (15% of patients). There was no correlation between the average duration
of use and number of pens dispensed per prescription (Pearson correlation coeffi-
cient -0.05). CONCLUSIONS: Results from the study indicate that the higher daily
dose (1.8mg) of liraglutide is used in ‘real world’ setting compared to pre-reim-
bursement assumptions. There are opportunity costs and clinical outcome impli-
cations arising from using the higher dose of liraglutide, given that there is no
robust evidence of additional benefits on glycaemic control from the higher dose.
This analysis highlights the role that monitoring can play in informing pharmaco-
economic evaluations and guideline recommendations post reimbursement.
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ACROMEGALY IN THE NETHERLANDS
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OBJECTIVES: To compare the potential cost of long-acting treatment with lan-
reotide vs octreotide for acromegaly using patient treatment characteristics from
the PHARMO Record Linkage System (RLS) in the Netherlands. METHODS: A cost
minimization model was used to compare the lifetime costs of the SSAs. Data for
patients receiving outpatient dispensing of long-acting SSA (2003–2010) were se-
lected from the PHARMO RLS. Acromegalic patients were identified by hospital
discharge diagnoses and were stratified by first SSA dispensed during the study
period. Dosing and injection intervals were assessed during stable treatment peri-
ods (i.e., the period of SSA dispensings with constant dosage and little variation in
injection intervals). RESULTS: Sixty-two octreotide LAR users and 16 lanreotide
Autogel users were identified. Stable treatment was observed in 46/62 (74%) oc-
treotide users and 12/16 (75%) lanreotide users. The median (IQR) duration of the
first stable phase was 3 (2-9) months for octreotide and 2 (1-3) months for lan-
reotide. During treatment stability, mean (SD) injection intervals were 28 (10)
for octreotide and 30 (6) for lanreotide; however, when patients were categorized
into weekly intervals, there were more users on shorter intervals with octreotide
than lanreotide (15/46 [33%] vs 2/12 [17%] injected every 3 weeks or more frequently
and 9/46 [19%] vs 3/12 [25%] injected every 5 weeks or less frequently respectively).
Based on similar dosing but longer injection intervals for lanreotide users, there
appeared to be a 5% lower average cost per acromegalic patient treated with lan-
reotide over octreotide. CONCLUSIONS: The longer injection interval observed
with the high dose lanreotide under stable long-acting SSA treatment resulted in
reduced costs compared to octreotide. However, the patient numbers of this rare
disease and the limited period of treatment stability limit the power to detect
differences between preparations.
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OBJECTIVES:Although the primary goal among patients with type 2 diabetes (T2D)
is gylcemic control, lack of patient education and health care access may represent
a major obstacle to proper disease management, particularly in emerging markets
such as Brazil. The aim of the current study was to document the level of patient
knowledge of HbA1c levels and its effect on health outcomes. METHODS: Data
were analyzed from the Brazil 2011 National Health and Wellness Survey, a cross-
sectional health survey of adults in Brazil (N12,000). Demographics (age, gender,
education, socioeconomic status, insurance type), health history (HbA1c level, FPG
level, frequency of testing), and health outcomes (health status using the SF-12v2,
work productivity loss using the WPAI, and health care resource use) were assessed
for all respondents. RESULTS: A total of 480 respondents (4.0%) reported a diagno-
sis of T2D of whom 85.38% did not know their level of HbA1c. Among those who
were aware of their HbA1c level, 60.34% reported being uncontrolled (i.e., a level
greater than 7%). Patients who were uncontrolled reported significantly worse
physical health status (39.43 vs. 46.68) and a significantly greater percentage work
overall impairment (42.93% vs. 25.58%) compared with those who were controlled
(all p.05). Access to care also was associated with better outcomes as those with
private insurance were significantly more likely to have an HbA1c test in the past 3
months (15.57% vs. 6.57%) and significantly less likely to have never been tested
(38.32% vs. 43.01%) than those with just public insurance (all p.05).
CONCLUSIONS: The lack of awareness of HbA1c levels suggests a significant gap in
patient education. Given the high probability of being uncontrolled, this lack of
patient education may have significant humanistic and economic consequences
for Brazil from a societal perspective. Improvement in access and education may
help improve overall T2D management.
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OBJECTIVES: Type 2 diabetes mellitus (DM2) patients are at long-term risk of car-
diovascular events and of microvascular complications that contribute to the bur-
den of the disease. The objective is to identify the main factors directly associated
to costs of DM2 care in Spain. METHODS: A systematic review of cost of disease
studies published in English or Spanish between January 2001 and December 2011.
A search of electronic databases [international and national] and hand search of
reference lists of key publications was performed. A methodological quality assess-
ment of reviewed publications applying the Center for Evidence Based Medicine
(CEBM, 2012) tool was performed. All costs updated to €, 2011. RESULTS: A total of
1505 articles were identified, 639 were excluded and 28 were retrieved. Total na-
tional health care expenditure intended for DM2 care in Spain was about €2,800
million per year. Direct costs varied between €851.23 and €4,882.80 per patient/year.
Main cost drivers were: other pharmacological treatments different from antidia-
betics (37.83%), hospital admissions (31.93%), medical visits (25.57%), and oral an-
tidiabetics (4.67%). Severe and moderate hypoglycemias increased costs 174 and 8
times, respectively, compared to those episodes with no need of medical care. DM2
costs increased by 59.5% if the goal of HbA1c7% was not reached; by 30% with
obesity, and by 64.5% if disease related complications appeared. Each 10% raise in
adherence to oral antidiabetic treatment represented a 2% to 4% reduction in DM2
costs. Levels of CEBM recommendation were 2c (16 studies), 3b (8 studies) and 4 (4
studies). CONCLUSIONS: Main factors directly associated to costs of DM2 care in
Spain were hypoglycemia, DM2 related complications, HbA1c control, obesity and
treatment adherence. Strategies aimed to improve these factors would have a
major impact on costs reduction.
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OBJECTIVES: To examine the association between obesity and hypoglycemia in
adults with type 2 diabetes (T2D), and assess whether hypoglycemic events (‘hy-
pos’) and obesity are related to health care use among these patients in France,
Germany, and the UK. METHODS: Data from the 2011 5EU National Health and
Wellness Survey were used (n57,512). All data were self-reported. T2D patients
were grouped according to frequency of hypos requiring assistance from others
(moderate/severe hypoglycemia); those reporting moderate/severe hypos at least
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